A ¥625m ($5.92m) loss posted by its Sagent operation in the US caused Nichi-Iko Pharmaceutical's group operating margin to shed just over a percentage point in the Japanese group’s financial first quarter ended 30 June 2019. The 1.1-point margin fall to just 3.7% came on a rise of a tenth in group turnover to ¥46.5bn.
Reflecting “intensified competition in the US market”, sales by the Sagent injectables segment tumbled by 30.7% to ¥6.76bn. The unit’s...







